Point of Care Nano-Technology (“PCNT”) seeks to provide consumers of healthcare with rapid and accurate on site “Actionable Diagnostic Information” that is backed by professional laboratory testing, where and when it is needed the most. .
Skyrocketing healthcare costs are driving the need for point of care and consumer self-care products that facilitate preventive medicine and early intervention.
Current Healthcare screening is highly inefficient with visiting the doctor’s office, being sent to the lab, waiting days or weeks to get the lab results and then going back to the doctor to be advised of the follow up treatment protocol. .
The ability to provide one visit diagnosis and treatment planning, including early diagnosis of certain diseases
and to monitor health status i,e. disease onset, progression and treatment outcomes in real time through noninvasive means is a highly desirable goal in healthcare promotion and delivery.
Late stage diagnosis, and therefore treatment, is a significant burden on private and public healthcare. For example early diagnosis of certain cancers greatly increases the five (5) year survival rates from as little as near 0 – 20% to as much as 80% or more.
Early stage intervention can be up to 20 to 30 times “less” costly than late stage treatment over the lifetime of the patient.
Oral fluid is a perfect medium to be utilized for health monitoring and disease detection and surveillance.
Nanotechnology is playing a pivotal role in various industry segments and nanotechnology based Point-of-Care (POC) products will enter the consumer market in large quantities and will have a significant impact on nearly all healthcare sectors.
PCNT has developed a nanotechnology enabled biomarker detection platform for Detection of DNA, RNA, protein analytes and Identification of diseased cells.
Governments across the world are beginning to feel the pressure to expand their healthcare systems and the need to provide affordable solutions to their rapidly growing and aging populations. Recent Market Forecast Reports are predicting the nanotechnology market to grow to $75.8B by 2020. This prospective growth will be largely driven by massive investment in nanotechnology R&D and commercialization by both governments and corporate worldwide.
For example, Kuwait is investing in national and visitor DNA database that would require all residents and visitors to submit their saliva specimen ahead of time or at the point of entry for rapid testing to enhance national security.